Company intelligence / Profile preview

AAZ-LMB

Paris region, France

Ownership: Private
Employees: ~400
Development stage: Other

Overview

AAZ-LMB manufactures and commercializes diagnostic tests and self-tests across multiple therapeutic areas. The company's flagship product autotest VIH® (HIV self-test) was the first of its kind launched in France in 2015[2] and is now available in approximately 17 European countries[2]. The company has expanded its portfolio to include gluten intolerance screening (autotest GLUTEN®, 2nd generation launched in 2019)[2], streptococcal throat infection testing (TROD'ANGINE®, authorized for use in French pharmacies)[2], and multiple COVID-19 diagnostic formats[2].

Therapeutic areas: GastroenterologyInfectious Diseases
Industry: Protein Biomarker Diagnostics

Beyond the preview

Go deeper on AAZ-LMB.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AAZ-LMB.

Explore the full profile